INTRODUCTION
The mammalian endometrium consists of epithelial and stromal cells. The proliferation of endometrial cells varies with cyclic changes of ovarian steroid hormone levels during the estrous cycle, and is controlled by ovarian steroid hormones. Estrogen stimulates the proliferation of endometrial epithelial cells, while simultaneous treatment with estrogen and progestin stimulates the proliferation of uterine stromal cells in adult mice (Huet-Hudson et al., 1989) . The steroid hormone-induced proliferation of endometrial cells is thought to be mediated by growth factors produced in endometrial stromal cells (Tomooka et al., 1986; DiAugustine et al., 1988; Beck and Garner, 1992; Das et al., 1994; Cooke et al., 1997) . Insulin-like growth factor 1 (IGF1) is expressed in all components of the mouse uterus and its expression is regulated by estrogen (Murphy et al., 1987; Ghahary et al., 1990; Kapur et al., 1992; Ohtsuki et al., 2007) . Moreover, IGF1 promotes the proliferation of endometrial cells (Shiraga et al., 1997; Sato et al., 2002; Inoue et al., 2005; Zhu et al., 2007) . These findings suggest that IGF1 is one of factors involved in the regulation of endometrial cell proliferation.
The insulin-like growth factor binding protein (IGFBP) family is composed of six subtypes, of which IGFBP3 is known to be the most abundantly expressed in many tissues. IGFBP3 modulates actions of IGF1 by forming an IGF1-IGFBP3 complex, resulting in the blockage of IGF1 actions or the prolongation of the half-life of IGF1 (Hwa et al., 1999; Duan and Xu, 2005) . IGFBP3 also directly inhibited cell proliferation by binding to an IGFBP3 receptor in an IGF-independent signaling pathway (Mochizuki et al., 2006) . Thus, IGFBP3 is likely to modulate actions of IGFs directly and indirectly in various tissues. The IGFBP3 receptor has been identified as a low-density lipoprotein receptor-related protein 1 (LRP1), which is also called transforming growth factor-β receptor type V (Leal et al., 1997; Danielpour and Song, 2006) . Lrp1 mRNA expression in the mouse uterus was studied to clarify the involvement of IGFBP3 receptors on the regulation of IGFBP3 actions within the endometrium.
IGFBP3 is expressed in the mouse uterus, and expression levels change during estrous cycle (Girvigian et al., 1994; Molnar and Murphy, 1994; Tang et al., 1994) . These findings suggest that uterine IGFBP3 production is partly regulated by ovarian steroid hormones. The present study was aimed at clarifying the role of IGFBP3 in the proliferation of endometrial cells and the effect of estradiol-17β (E2) on IGFBP3 production in endometrial cells. Primary cultures of mouse endometrial epithelial and stromal cells were used in the present study.
In recent studies, epidermal growth factor (EGF) suppressed IGFBP3 expression in human cervical epithelial cells and esophageal epithelial cells (Hembree et al., 1994; Takaoka et al., 2006) . Furthermore, excess expression of heparin-binding epidermal growth factor (HB-EGF) lowered IGFBP3 expression (Provenzano et al., 2005) . These findings suggest that the production of IGFBP3 is partly regulated by members of the EGF family. Transforming growth factor α (TGFα), a member of the EGF family, is detected in the mouse uterus during the peri-implantation period (Tamada et al., 1991) . In addition, TGFα expression is regulated by estrogen (Nelson et al., 1992) . These observations led to the idea that TGFα is involved in the regulation of IGFBP3 expression in the mouse uterus. In the present study, we investigated the effect of TGFα on IGFBP3 expression in endometrial cells.
MATERIALS AND METHODS

Animals
Immature (21 to 23 days old) and adult (8 weeks old) female mice of the ICR strain were used in the present study. They were housed in a temperature-controlled animal room and were fed a commercial diet of CA-1 (CLEA Japan, Osaka) and tap water. All animal care and experiments were conducted in accordance with the Guidelines for Animal Experimentation of Okayama University, Japan.
Cell culture
Uterine epithelial and stromal cells were isolated according to methods used in previous studies (Ross et al., 1993; Shiraga et al., 1997; Komatsu et al., 2003) . Isolated uterine epithelial cells were seeded on collagen-coated culture wells at a density of about 5×10 4 cells/cm 2 . Isolated stromal cells separated from epithelial cells were seeded on poly-L-lysine coated culture wells at a density of about 6×10 4 cells/cm 2 . Stromal cells were first cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium without phenol red (DME/F12, Sigma Aldrich, St. Louis, MO, USA) containing 2% dextran-coated charcoal-treated fetal bovine serum. After a 1 day pre-culture, the cells were cultured in serum-free DME/F12 supplemented with BSA (1 g/l), hydrocortisone (100 μg/l), triiodothyronine (400 ng/l), transferrin (10 mg/l), glucagon (10 ng/l), parathormone (200 ng/l), sodium selenite (5 μg/l), and insulin (100 μg/l). The plates were incubated at 37°C in an atmosphere of 5% CO2, and the medium was changed every 2 days.
E2 and progesterone (P4) (Sigma-Aldrich) were initially dissolved in ethanol to yield 10 μM stock solutions (0.03% and 0.01% ethanol, respectively). Working solutions of E2 and P4 were made by diluting the stock solutions with culture medium. AG1478 (Biomol International, Plymouth Meeting, PA, USA) was initially dissolved in dimethyl sulfoxide (DMSO) (10 μM; 0.01% DMSO) and later diluted with culture medium.
Determination of DNA synthesis
DNA synthesis was assayed by immunochemical detection of 5'-bromo-2'-deoxyuridine (BrdU) incorporation into the cell nucleus by using a Cell Proliferation ELISA, BrdU Kit (Roche Diagnostics, Mannheim, Germany). Cultured cells were treated with 100 ng/ml recombinant human IGF1 (Amersham Pharmacia Biotech, Uppsala, Sweden) with or without recombinant mouse IGFBP3 (R&D Systems, Minneapolis, MN, USA) for 16 or 48 hr. These cells were exposed to 100 μM BrdU for the last 4 hr. The cells were then fixed and incubated with a peroxidase-conjugated anti-BrdU monoclonal antibody from mouse-mouse hybrid cells (Anti-BrdU-POD). After washing, tetramethyl-benzidine was added as a substrate. The peroxidase reaction was stopped with 0.2 M sulfuric acid, and the absorbance at 450 nm was measured with a micro-plate reader (Bio-Rad, Hercules, CA, USA).
cDNA synthesis and PCR amplification
Total RNA was prepared from cultured endometrial cells and the whole uterus by using a single-step method (Chomczynski and Sacchi, 1987) , and was transcribed by using Thermoscript Reverse Transcriptase (Invitrogen, CA, USA) according to the manufacturer's instructions. Primers purchased from Invitrogen are listed in Table 1 . PCR was performed with Takara Taq (Takara Bio, Otsu, Japan) and a Gene Amp PCR System 9700 thermal cycler (Applied Biosystems, Branchburg, NJ, USA). PCR conditions were: 20 sec at 94°C; an appropriate number of cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec; and 10 min at 72°C. A 10-μl aliquot of each reaction was electrophoresed on 2% agarose gel, stained with ethidium bromide, and photographed under ultraviolet rays. Signal intensities were measured with the Kodak 1D Imaging System (Eastman Kodak, CT, USA). The amount of each target mRNA was normalized to the amount of ribosomal protein L19 (Rpl19) mRNA.
Western blot analysis of IGFBP3
Culture media (400 μl) were concentrated by lyophilization. The concentrated media were subjected to 12.5% SDS-PAGE and transferred to nitrocellulose membrane (Schleicher & Schuell, Keene, NH, USA). The membranes were blocked for 1 hr with 1% bovine serum albumin (BSA) dissolved in Tris-buffered saline containing 0.1% Tween-20, and were then incubated sequentially with goat anti-mouse IGFBP3 antibody (1:1,000, R&D Systems, MN, USA) and horseradish peroxidase conjugated anti-goat secondary antibody (1:5,000, Santa Cruz Biotechnology, CA, USA). Peroxidase activity was detected by using luminol (Sigma Aldrich) and a hydrogen peroxide reaction. Recombinant mouse IGFBP3 (R&D Systems) was used as a positive control.
Statistical analysis
Data were expressed as the mean±SEM. Differences among groups were analyzed by analysis of variance followed by Tukey's test. 
RESULTS
Igfbp3
, Igf1, and Igf1r mRNA levels in the mouse uterus during the estrous cycle Igfbp3, Igf1, and Igf1r mRNA levels in the mouse uterus were analyzed at 24-hr intervals during the estrous cycle by using semi-quantitative RT-PCR. Igfbp3 and Igf1r mRNA levels were highest at diestrus 1 during the 4-day estrous cycle. In contrast, Igf1 mRNA levels were highest at proestrus (Fig. 1) .
IGFBP3 inhibited IGF1-induced DNA synthesis in endometrial cells
Endometrial epithelial and stromal cells were treated with recombinant mouse IGFBP3 with or without IGF1 (100 ng/ml) to study effect of IGFBP3 on DNA synthesis. Based on a preliminary study, we measured DNA synthesis by detecting BrdU uptake 48 hr after IGF1/IGFBP3 treatment in endometrial epithelial cells, or 16 hr in stromal cells (Shiraga et al., 1997; Inoue et al., 2005) . IGF1 stimulated DNA synthesis in both endometrial epithelial and stromal cells, and IGFBP3 inhibited this stimulatory effect of IGF1 in a dose-dependent manner (Fig. 2 ).
E2 and TGFα suppressed IGFBP3 expression in endometrial stromal cells
Igf1, Igfbp3, Igf1r, and Lrp1 mRNA levels in endometrial stromal cells were analyzed by using semi-quantitative RT-PCR. E2 treatment increased Igf1 mRNA levels after 24 hr, whereas Igfbp3 mRNA levels decreased. E2 had no effect on Lrp1 or Igf1r mRNA levels (Fig. 3) .
The effect of TGFα on Igfbp3 mRNA levels in endometrial cells were studied, because Tgfa and Egfr mRNAs are both expressed in mouse endometrial cells, and EGF family growth factors are involved in IGFBP3 production in various tissues and cells. E2 significantly stimulated Tgfa mRNA expression in endometrial stromal cells (Fig. 4A) . In endometrial stromal cells, TGFα reduced Igfbp3 mRNA expression in a dose-dependent manner, but did not affect Lrp1 mRNA levels (Fig. 4B) .
Endometrial stromal cells were treated with E2 or TGFα, and the cellular Igfbp3 mRNA levels ( Fig. 5A ) and IGFBP3 protein levels in the culture media were analyzed by western blotting (Fig. 5B) . Recombinant mouse IGFBP3 was used as a positive control, and two immunoreactive bands of 35 kDa Fig. 1 . Expression of Igfbp3, Igf1, and Igf1r mRNA in the uterus during the estrous cycle. Uteri were obtained from adult female mice at each stage of the estrous cycle. The upper panel shows ethidium bromide-stained electrophoretic patterns of PCR products. Band intensities were measured, and normalized according to the Rpl19 mRNA levels. L, 100-bp DNA ladder; P, proestrus; E, estrus; D1, 1st day of diestrus; D2, 2nd day of diestrus. In the histograms, each column represents a mean±SEM. The data are shown as relative values compared to that at proestrus. The number in each column indicates the number mice used. *, p<0.01; **, p<0.05, significantly different between stages of the estrous cycle. and 40 kDa were detected. In the culture media of endometrial stromal cells, two immunoreactive bands were also detected (37 and 42 kDa). After 48 hr, both E2 and TGFα decreased the Igfbp3 mRNA and secreted IGFBP3 protein levels.
AG1478 inhibited the TGFα effect on Igfbp3 mRNA expression, but not the effect of E2
Endometrial stromal cells were treated with AG1478, an inhibitor of the tyrosine kinase of the EGFR, in the presence of TGFα or E2, to examine the TGFα signaling pathway involving EGFR. AG1478 nullified the inhibitory effect of TGFα on Igfbp3 mRNA expression, but did not restore the E2-induced suppression of Igfbp3 mRNA expression (Fig. 6 ).
Igfbp3 mRNA expression was not decreased by E2 or TGFα in endometrial epithelial cells
Endometrial epithelial cells were treated with E2 or TGFα, and their cellular Igfbp3 mRNA levels were analyzed after 24 hr. E2 increased Igfbp3 mRNA in a dose-dependent manner (Fig. 7A ), but TGFα had no effect on Igfbp3 mRNA expression (Fig. 7B ).
P4 increased Igfbp3 mRNA levels in endometrial stromal cells, but not in endometrial epithelial cells
Endometrial epithelial and stromal cells were treated with E2 (10 -9 M) and/or P4 (10 -7 M), and harvested 24 hr after the treatment to study the involvement of P4 in Igfbp3 mRNA expression. In endometrial epithelial cells, P4 increased Igfbp3 and Igf1r mRNA levels in the presence of E2, and E2 alone increased Igfbp3 mRNA levels, as already shown (Fig. 8A) . In endometrial stromal cells, P4 increased Igfbp3 mRNA levels. E2 increased Igf1 mRNA levels and decreased Igfbp3 mRNA levels, but P4 did not nullify the E2-induced decrease in Igfbp3 mRNA levels (Fig. 8B) .
DISCUSSION
IGFBPs are known to modulate actions of IGF1 and IGF2 in various tissues, and IGFBP3 has been widely shown to inhibit cell proliferation (Huynh et al., 2002; Mishra and Murphy, 2004; Strange et al., 2004; Duan and Xu, 2005) . The present study demonstrated, for the first time, that IGFBP3 exerts an inhibitory effect on the proliferation of mouse endometrial cells in the presence of IGF1. IGF1 stimulates DNA synthesis in endometrial epithelial and stromal cells (Shiraga et al., 1997; Sato et al., 2002; Inoue et al., 2005; Zhu et al., 2007) . IGFBP3 treatment nullified this stimulatory effect of IGF1 on endometrial cells, but IGFBP3 alone did not affect DNA synthesis in endometrial stromal cells. Although the binding of IGFBP3 to IGF1 in our culture system for mouse endometrial cells was not ascertained in the present study, IGFBP3 released from endometrial cells probably modulates IGF1 actions in an autocrine or paracrine manner.
The anti-proliferative effects of IGFBPs, including IGFBP3, occur through IGF-independent mechanisms as well as IGF-dependent ones (Huang et al., 2003; Cavaille et al., 2006; Mochizuki et al., 2006) . Lrp1 mRNA was detected in endometrial epithelial and stromal cells, but IGFBP3 alone did not affect DNA synthesis in the endometrial cells. These results suggest that the IGF-independent anti-proliferative action of IGFBP3 did not function, at least in our culture system for mouse endometrial cells. It is not clear what actions of IGFBP3 are regulated through Lrp1, the IGFBP3 receptor expressed in endometrial cells.
E2 decreased IGFBP3 expression in endometrial stromal cells, which is consistent with previous studies of uteri in several species (Molnar and Murphy, 1994 ; , 10 -8 M) or TGFα (0, 0.1, 1, 10, 20 ng/ml) for 24 hr. Igfbp3 mRNA levels were analyzed by semi-quantitative RT-PCR. Each column represents the mean±SEM of triplicate wells. Experiments were replicated three times. L, 100-bp DNA ladder; *, p<0.05, significantly different from control. Kleinman et al., 1995; Liu et al., 1997; Peterson et al., 1998) . The E2-induced decrease in Igfbp3 mRNA levels was inhibited by pure antiestrogen ICI182,780 (data not shown). The mechanism by which estrogen regulates Igfbp3 expression is not clear. The promoter of rat Igfbp3 has been characterized, and contains two contiguous sequences showing 80% similarity with the consensus estrogen response element (ERE) (Albiston et al., 1995) . The 5'-flanking region of mouse Igfbp3, the putative promoter, also contains an ERE-like sequence. Functional analysis of the promoter of mouse Igfbp3 is needed.
Igf1 mRNA levels changed during the estrous cycle, which was consistent with our previous report (Ohtsuki et al., 2007) . Estrogen stimulates Igf1 transcription (Murphy et al., 1987; Ghahary et al., 1990; Kapur et al., 1992; Zhou et al., 1994; Ohtsuki et al., 2005) , and high levels of circulating estrogen at proestrus induced high Igf1 mRNA levels. Igf1r mRNA levels also changed during the estrous cycle; they were high at diestrus and low during proestrus and estrus, suggesting that the responsiveness of endometrial cells to IGF1 depends upon the stage of the estrous cycle, and possibly upon levels of estrogen and progestin. Since estrogen induced Igf1r mRNA expression only in endometrial epithelial cells, Igf1r mRNA expression may be regulated in tissuespecific manner.
Igfbp3 mRNA levels were highest at diestrus and low during proestrus and estrus. This reduction in Igfbp3 mRNA levels may have been caused by high circulating estrogen levels, since estrogen decreased Igfbp3 mRNA levels in endometrial stromal cells. Importantly, the change in Igfbp3 mRNA levels during the estrous cycle was in a pattern opposite to that of Igf1 mRNA expression. IGF1 is regarded as one of the growth factors controlling the estrogen-induced proliferation of endometrial cells. IGF1 has been shown to stimulate DNA replication in both endometrial epithelial and stromal cells (Shiraga et al., 1997; Inoue et al., 2005) . In the present study, the mitogenic action of IGF1 was depressed by high levels of IGFBP3. Therefore, estrogen probably stimulates IGF1 action in the mouse endometrium by stimulating Igf1 transcription and inhibiting Igfbp3 transcription. The correlation between the expression of Igf1 and Igfbp3 and the proliferation of endometrial cells during the estrous cycle remains to be studied.
Progestin is essential for the initiation of the cell cycle in endometrial stromal cells. P4 stimulates the proliferation of endometrial stromal cells in the presence of estrogen (Komatsu et al., 2003) , although estrogen alone does not stimulate proliferation (Quarmby and Korach, 1984) . P4 alone increased Igfbp3 mRNA expression in endometrial stromal cells, while P4 had no effect on Igfbp3 mRNA expression in endometrial epithelial cells. Furthermore, P4 did not affect the E2-induced down-regulation of IGFBP3 expression. These findings correspond well to in-vivo data showing that Igfbp3 mRNA levels are high at diestrus 1 and 2, during which circulating levels of P4 are also high (Smith et al., 1975) . Circulating levels of estrogen and progestin are higher at estrus. High levels of estrogen will reduce the effect of progestin on IGFBP3 expression. However, circulating levels of estrogen decrease from proestrus, and progestin is dominant during late estrus and diestrus. Therefore, progestin stimulates IGFBP3 production from endometrial stromal cells at diestrus.
Igfbp3 mRNA was detected by in situ hybridization in the endometrial stromal cells juxtaposed to endometrial epithelial cells in the rat uterus, but was not detected in the endometrial epithelial cells (Girvigian et al., 1994) . Igfbp4 mRNA was detected in endometrial luminal epithelial cells. Interestingly, estrogen increased Igfbp3 mRNA expression in endometrial epithelial cells, indicating that estrogen differentially regulates Igfbp3 transcription in a tissue-specific manner.
The roles of IGFBP3, produced in endometrial epithelial cells, are not clear. The proliferation of endometrial epithelial cells was mainly regulated by growth factors produced in endometrial stromal cells, and levels of IGFBP3 secreted from endometrial epithelial cells may be low compared to those of endometrial stromal cells, even if estrogen stimulated Igfbp3 transcription in the epithelial cells. Hence, epithelial IGFBP3 may not be involved in the estrogen-induced proliferation of endometrial epithelial cells.
We previously showed that TGFα acts as a mitogenic factor in endometrial stromal cells (Komatsu et al., 2003) . In the present study, we demonstrated for the first time that TGFα decreases IGFBP3 expression in mouse endometrial stromal cells. Members of the EGF family, such as EGF and HB-EGF, have been shown to reduce IGFBP3 expression in various cell types (Hembree et al., 1994; Wraight and Werther, 1995; Provenzano et al., 2005; Takaoka et al., 2006) . In contrast, TGFα stimulates IGFBP3 synthesis in human mammary epithelial cells (Sivaprasad et al., 2004) . Thus, TGFα exhibits opposite effects on the modulation of IGFBP3 expression, according to cell type.
In mouse endometrial stromal cells, TGFα induced inhibition of Igfbp3 mRNA expression by way of EGFR signaling, because AG1478 blocked TGFα inhibition of Igbp3 mRNA expression. In contrast, the E2-induced decrease in Igfbp3 mRNA levels in endometrial stromal cells was not recovered by AG1478, indicating that EGFR signaling was not involved in E2 inhibition of Igfbp3 mRNA expression, although E2 stimulated TGFα expression. These results suggest that E2 and TGFα act separately on Igfbp3 expression.
The proliferation of endometrial cells is regulated by growth factors, including IGF1 produced in endometrial stromal cells (Bigsby and Cunha, 1986; Astrahantseff and Morris, 1994; Cooke et al., 1997; Pierro et al., 2001 ). IGF1 expression and IGFBP3 expression were conversely regulated by estrogen in endometrial stromal cells. Up-regulation of IGF1 expression and down-regulation of IGFBP3 expression by estrogen in the endometrial stromal cells was demonstrated, which suggests that estrogen enhances IGF1 action through the reduction of IGFBP3 expression at the transcription level. TGFα, whose production was stimulated by estrogen, decreased IGFBP3 production at the level of transcription, resulting in the enhancement of IGF1 action. These results suggest that estrogen suppresses IGFBP3 production in multiple ways, and stimulates the proliferation of endometrial cells through the enhancement of IGF1 action.
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